Compugen Ltd. delivered a remarkable financial recovery in FY2025, posting over 160% revenue growth coupled with operating profitability for the first time in several years. This turnaround was propelled by milestone licensing revenues from its proprietary immuno-oncology programs discovered via its AI/ML computational platform, Unigen™. Clinically, the lead internal asset COM701 advances through a blinded randomized ovarian cancer trial, while collaborations with AstraZeneca and Gilead underpin risk-sharing and validation of pipeline assets. Despite worsening operating cash flow compared to the prior year, Compugen maintains strong liquidity and is reinvesting capital internally without dividends or buybacks. Near-term catalysts include the expected interim analysis of COM701’s maintenance ovarian cancer study in early 2027.